India's JB Chemicals & Pharmaceuticals posts profit jump on strong domestic demand

J B Chemicals and Pharmaceuticals

11/11/2025 12:09

Nov 11 (Reuters) - India's JB Chemicals & Pharmaceuticals JBCH.NS reported a year-on-year jump in profit for the September quarter on the back of strong demand in the domestic market.

The company, which makes the Rantac antacid, reported consolidated net profit of 2.08 billion rupees ($23.7 million) for the second quarter, compared with 1.75 billion rupees a year earlier.

"JB's domestic business continued to outperform the market, with all major brands delivering robust growth," CEO Nikhil Chopra said in a statement.

The drugmaker's overall revenue climbed 8% to 10.85 billion rupees in the quarter.

For further results highlights, click here.

KEY CONTEXT

The company has been outperforming the Indian pharmaceutical market, with JB Chemicals growing 12% against the markets' 8% growth, as per clinical research firm IQVIA's moving annual total data for September.

JB Chemicals' domestic business revenue rose 9%, while revenue from its international business rose 7%.

PEER COMPARISON:

Valuation (next 12 months)
Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Price/Sales
Revenue growth (%)
Profit growth (%)
Mean rating*
No. of analysts
Stock to price target**
Div yield (%)
J B Chemicals and Pharmaceuticals
JBCH.NS
32.48
21.19
5.57
11.50
18.00
Buy
11
0.92
0.68
Glenmark Pharmaceuticals
GLEN.NS
24.54
15.34
NULL
10.44
30.38
Buy
9
0.80
0.20
Torrent Pharmaceuticals
TORP.NS
46.93
27.18
7.98
17.11
20.10
Buy
29
0.96
0.84
Mankind Pharma
MNKI.NS
38.00
25.09
6.09
14.28
18.56
Buy
16
0.84
0.04

* The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

JULY-SEPTEMBER STOCK PERFORMANCE

-- All data from LSEG

($1 = XX Indian rupees)

($1 = 87.8950 Indian rupees)

JB Chemicals Stock Performance https://tmsnrt.rs/3WRjqKp

 (Reporting by Vijay Malkar in Bengaluru; Editing by Harikrishnan Nair)

 ((VijayDattaram.Malkar@thomsonreuters.com;))